- Lancet review: Vitamin D marker for deteriorating health
- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- Lumene unveils product innovation, new packaging for 2014
- Study: Vitamin D supplementation may augment chronic hive therapy
- Study: 2,000 IUs of vitamin E daily effective in slowing functional decline in AD patients
BOSTON — For patients in the early stages of multiple sclerosis, low levels of vitamin D were found to strongly predict disease severity and hasten its progression, according to a new study led by the Harvard School of Public Health investigators in collaboration with Bayer HealthCare. The findings suggest that patients in the early stages of MS could stave off disease symptoms by increasing their vitamin D intake.
"Because low vitamin D levels are common and can be easily and safely increased by oral supplementation, these findings may contribute to better outcomes for many MS patients," said lead author Alberto Ascherio, professor of epidemiology and nutrition at HSPH.
The study appeared online January 20, 2014 in JAMA Neurology.
Previous research indicated a connection between low levels of vitamin D and risk of developing MS or having MS symptoms worsen, but those studies included patients with longstanding MS whose vitamin D levels could partly be a consequence, not a predictor, of disease severity. The new study looked at vitamin D levels among patients at the time of their first symptoms of the disease.
Researchers found that early-stage MS patients who had adequate levels of vitamin D had a 57% lower rate of new brain lesions, a 57% lower relapse rate and a 25% lower yearly increase in lesion volume than those with lower levels of vitamin D. Loss in brain volume, which is an important predictor of disability, also was lower among patients with adequate vitamin D levels. The results suggest that vitamin D has a strong protective effect on the disease process underlying MS, and underscore the importance of correcting vitamin D insufficiency, which is widespread in Europe and the United States, the researchers said.
"The benefits of vitamin D appeared to be additive to those of interferon beta-1b, a drug that is very effective in reducing MS activity. The findings of our study indicate that identifying and correcting vitamin D insufficiency should become part of the standard of care for newly diagnosed MS patients," Ascherio said.